Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2018
Price : $35 *
At a glance
- Drugs Allogeneic stem cell therapy Athersys (Primary)
- Indications Liver transplant rejection
- Focus Adverse reactions
- Acronyms MiSOT; MISOT-I
- 24 Mar 2017 Status changed from recruiting to discontinued.
- 18 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
- 16 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov record.